Lytica Therapeutics is an innovative company focused on advancing antibody-drug conjugates (ADCs) through its proprietary technologies. Central to its approach is the SIP (Stapled Internalization Promoter) technology, which significantly enhances the internalization and efficacy of ADCs. This technology allows for a wide compatibility of linkers and offers flexibility in the peptide-antibody ratio, enabling the development of highly effective therapeutic agents. Lytica's S.P.A.C.E. (Stapled Peptide Antibody Conjugate Engineering) platform further optimizes the design of antibody conjugates, addressing the critical challenge of receptor internalization that often limits the effectiveness of current ADCs.

The company is currently in the preclinical stage, focusing on a pipeline that includes high internalization ADCs targeting various cancers such as ovarian, multiple myeloma, breast, lung, and colorectal cancers. Lytica's modular platform not only facilitates the optimization of antibody scaffolds and linker constructs but also allows for the selection of ideal payloads, including small molecules and oligonucleotides. This versatility positions Lytica at the forefront of antibody conjugate development, aiming to broaden the therapeutic applications of ADCs and enhance their precision in targeting cancer cells.

United States

Lytica Therapeutics is a Cambridge-based biotech company developing novel peptide conjugates for next-generation ADCs. The secret to unlocking more effective ADCs is in the...

Lytica Therapeutics

Company Details